Unity Biotechnology — Technical Presentation (April 2023)
21 slides from Unity Biotechnology's technical presentation, Apr 24, 2023
Slide 1: UBX1325 Phase 2 BEHOLD Study in DME 48 Week Top Line Results
NASDAQ: UBX UBX1325 Phase 2 BEHOLD Study in DME 48 Week Top Line Results Robert Bhisitkul, M.D., Ph.D. Professor of Ophthalmology, UCSF Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2
Slide 2: Special Note Regarding Forward-Looking Statements
Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence and the role it plays in diseases of aging, the pote
Slide 3: Top Line Results, Mechanism of Action, Clinical Development Plan
Top Line Results UBX1325 Mechanism of Action Clinical Development Plan
Slide 4: UBX1325 Led to Statistically Significant and Clinically Meaningful Improvement in Visual Acuity in DME
UBX1325 Led to a Statistically Significant and Clinically Meaningful Improvement in Visual Acuity in Patients with Diabetic Macular Edema Through 48 Weeks A single dose of UBX1325 demonstrated: UBX1325-treated patients had a significant improvement in BCVA of +6.2 ETDRS letters from baseline and +5.
Slide 5: UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells
UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision UNITY illustration 24 April 2023 DME: Increased senescence burden Poor barrier function Production of inflammatory factors Loss of retinal function DME treated with Senolytic (intended
Slide 6: UBX1325 Clinical Program Overview
UBX1325 Clinical Program Overview Safety & Tolerability Safety & Efficacy 2020 2021 2022 2023 Phase 1 ENVISION: Phase 2 nAMD Study BEHOLD: Phase 2 DME Study SAD 24-Week Follow-up nAMD 24 Week Follow-up SAD Study - up to 10 µg 4Q ‘21 1H ‘22 2H ‘22 Long-Term Extension DME Proof of Concept Study (First
Slide 7: Context for 24wk DME Data After Anti-VEGF Effect Plateaued
Context for 24wk DME Data: After Anti-VEGF Effect Has Plateaued, Patients Gain Approximately 1 Letter in Subsequent 6 Months on Aflibercept Treatment VISTA BLA 125387 Suppl 48, 25 Mar 2015 24 April 2023
Slide 8: UBX1325 Ph2 BEHOLD Study 48-week data in patients with DME
UBX1325 Ph2 BEHOLD Study 48-week data in patients with DME 24 April 2023
Slide 9: BEHOLD Study Design, Patient Population, and Endpoints
BEHOLD Study Design, Patient Population, and Endpoints Source: t_14_1_1 24 April 2023 Individuals with Diabetic Macular Edema Repeated anti-VEGF treatments (≥2 injections/6 months) – Actual: 4.1 injections in prior 6 months Residual retinal fluid (≥300 µm) – Actual: 439.6 µm Visual acuity deficit (7
Slide 10: Patient characteristics at baseline were well balanced between groups
Patient characteristics at baseline were well balanced between groups Source: t_14_1_2 24 April 2023 Parameter, Units (SD) Sham UBX1325 Age, Years 61.4 (9.09) 63.6 (9.33) HBA1c, % 7.4 (1.36) 8.0 (1.68) Diabetes Dx, Years 17.5 (10.53) 17.2 (11.41) DME Dx, Years 3.0 (2.32) 3.5 (3.60) BCVA, ETDRS lette
Slide 11: Marked drop in need for anti-VEGF rescue beyond week 18 vs Sham
UBX1325-treated patients had marked drop in need for anti-VEGF rescue beyond week 18 compared to Sham-treated patients through 48 weeks Source: f_km_plots_listings; f_km_plots 24 April 2023 * p = 0.0159 Log-Rank * Median Time to First Rescue Sham: 17.5 Weeks Efficacy analyses excluding and including
Slide 12: Significant improvement in BCVA of 6.2 letters at 48 weeks
* * * * * * * * * * * UBX1325-treated patients had a significant improvement in BCVA from baseline† of 6.2 letters at 48 weeks (excluding data post-rescue) Source: f_14_2_1_1; t_14_2_1_1 24 April 2023 * p < 0.05 vs. baseline BCVA CFBL (ETDRS Letters) UBX1325 Sham Delta Between Group p-value Week 24
Slide 13: Significant visual acuity gains vs Sham based on last observation prior to rescue
UBX1325-treated patients had significant visual acuity gains compared to Sham based on analysis of last observation prior to rescue or end of study† Source: f_14_2_1_35 24 April 2023 * Last observation carried forward (to rescue or end of study participation) † Supplemental Analysis Mean BCVA change
Slide 14: Significant BCVA improvement from baseline at all timepoints including post-rescue data
At all timepoints, UBX1325-treated patients had a statistically significant improvement in BCVA from baseline† (including post-rescue data) Source: f_14_2_1_13; t_14_2_1_2 24 April 2023 All points p < 0.05 vs. baseline except Sham Weeks 4, 24 and UBX Week 8 NS: not significant BCVA CFBL (ETDRS Lette
Slide 15: 50% of UBX1325-treated patients gained at least letters of vision through 48 weeks
50% of UBX1325-treated patients gained at least 5 letters of vision through 48 weeks, with over 20% gaining at least 10 letters (excluding post-rescue data) Source: t_14_2_4_1 24 April 2023
Slide 16: CST remained stable in UBX1325 patients compared to worsening in Sham
CST remained stable in UBX1325-treated patients compared to worsening in Sham patients (excluding post-rescue data) Source: f_14_2_1_2; t_14_2_1_3 24 April 2023 Sham: p < 0.15 vs BL all points except Weeks 1 and 48 UBX: All points not significantly different from baseline NS: not significant BCVA CF
Slide 17: Mean CST lower in UBX1325 patients vs Sham at 48 weeks
Mean CST was significantly lower in UBX1325-treated patients compared to Sham patients at 48 weeks (including post-rescue data) Source: f_14_2_1_14; t_14_2_1_4 24 April 2023 NS: not significant * * * * * * * p < 0.15 vs. BL BCVA CFBL (ETDRS Letters) UBX1325 Sham Delta Between Group p-value Week 24 -
Slide 18: 53.1% of UBX1325 patients did not require anti-VEGF rescue through 48 weeks
53.1% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks compared to 21.9% of Sham patients Source: f_14_2_4_1; t_14_2_2_1 24 April 2023 UBX vs. Sham p = 0.0096 Rescue Criteria (Either) Decrease of 10 ETDRS or more letters from any peak value Increase in CST of 75 µm or mo
Slide 19: UBX1325 demonstrated favorable safety and tolerability with no intraocular inflammation
UBX1325 demonstrated a favorable overall safety and tolerability profile with no instances of intraocular inflammation Source: t_14_3_1_1 24 April 2023 Parameter, No. of Patients Sham (N = 33) UBX1325 10 µg (N = 32) Subjects with at least one TEAE 31 (93.9) 26 (81.3) Related TEAE 3 (9.1) 6 (18.8) Gr
Slide 20: Summary of Findings and Concordance of Evidence Supporting Treatment Effect
Summary of Findings and Concordance of Evidence Supporting a Treatment Effect of UBX1325 in Diabetic Macular Edema Had a generally favorable safety and tolerability profile with no intraocular inflammation Led to a majority of patients achieving a rescue-free interval of at least 48 weeks and may re
Slide 21: Q&A
BIOTECHNOLOGY Q&A
Unity Biotechnology — Technical Presentation (April 2023) on 6ix